EMMA News and Press, Emmaus Life Sciences Incorporation From 07/08/20

TORRANCE, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today announced it will be restating its previously issued audited consolidated financial statements for the twelve months ended December 31, 2018 and u...

TORRANCE, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today that it was issued a license from the Israeli Ministry of Health on June 17, 2020 granting marketing authorization for the commercial di...

TORRANCE, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, today reported that on June 22, 2020 the National institutes of Health (NIH) issued a Notice that the National Cancer Institute, an institute of the NIH...

Quick Take Forma Therapeutics Holdings ( FMTX ) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement. The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers. FMTX...

DENVER, Colo., June 5, 2020- Shift4 Payments Inc. (NYSE:FOUR) begins trading today, after pricing its initial public offering at $23 per share last night. The payment-processing tech company’s IPO price is above its projected $19 to $21 per share range, as it expects to raise $345 million...

TORRANCE, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, provided today operational updates in advance of the filing of its 10-K for the year ended December 31, 2019 and its 10-Q for the first quarter of 2020....

TORRANCE, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease treatment, announced today that APCER Life Sciences (APCER) has confirmed the safety profile of Endari ® , Emmaus’ prescription grade L-glutamine oral...

TORRANCE, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a leader in sickle cell disease  treatment, announced today that the SFDA (Saudi Food & Drug Authority) has accepted its request for priority review of Endari ® , its prescription ...

NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from its inaugural conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive...

NEW YORK, March 24, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its inaugural event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and...